Sanofi announces closing of Regeneron stock sale

Libtayo® (cemiplimab-rwlc) longer-term results in advanced cutaneous squamous cell carcinoma presented at ASCO 2020 show durable responses that deepen over time

Sanofi names new leaders to Executive Committee

Sanofi’s Board of Directors notes the resignation of Emmanuel Babeau and coopts Gilles Schnepp as Independent Director

Sanofi announces pricing of Regeneron stock offering

Sanofi: FDA approves Dupixent® (dupilumab) as first biologic medicine for children aged 6 to 11 years with moderate-to-severe atopic dermatitis

Sanofi intends to sell its equity investment in Regeneron; confirms no change to ongoing collaboration

Dupixent® (dupilumab) eosinophilic esophagitis trial meets both co-primary endpoints

Sanofi to highlight pipeline programs in a series of interactive virtual sessions leading to a R&D day event

FDA grants priority review of sutimlimab, potential first approved treatment of hemolysis in adult patients with Cold Agglutinin Disease